Cite
HARVARD Citation
Hirsh Raccah, B. et al. (2021). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. International journal of cardiology. pp. 7-14. [Online].